Related Experiment Video

Updated: Jun 15, 2026

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

Sonia Vallet1, Siddhartha Mukherjee, Nileshwari Vaghela

  • 1Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

Proceedings of the National Academy of Sciences of the United States of America
|March 3, 2010
PubMed

Insights

Activin A drives multiple myeloma bone destruction by inhibiting bone-forming cells. Targeting activin A with a decoy receptor reversed this damage and slowed tumor growth in preclinical models.

Area of Science:

  • Oncology
  • Bone Biology
  • Molecular Biology

Background:

  • Cancer-related bone disease pathogenesis is key for new therapies.
  • Multiple myeloma (MM) exploits its microenvironment, favoring osteolysis.
  • Understanding MM's impact on bone is critical.

Purpose of the Study:

  • Identify therapeutic targets in cancer-related bone disease.
  • Investigate activin A's role in multiple myeloma osteolysis.
  • Evaluate activin A as a therapeutic target for MM bone disease.

Main Methods:

  • Measured activin A levels in MM patients with osteolytic disease.
  • Examined MM cell and marrow stromal cell interactions.
  • Assessed activin A's effect on osteoblast differentiation via SMAD2/DLX5 signaling.
  • Tested a soluble decoy receptor targeting activin A in a humanized MM model.

Main Results:

  • Elevated bone marrow plasma activin A levels correlate with osteolytic MM.
  • MM cells enhance activin A secretion through JNK activation.
  • Activin A inhibits osteoblast differentiation by down-regulating DLX5.
  • Targeting activin A reversed osteoblast inhibition and improved bone disease in vivo.

Conclusions:

  • Activin A is a key mediator of multiple myeloma-induced osteolysis.
  • Targeting activin A offers a promising therapeutic strategy for MM bone disease.
  • Further clinical trials are warranted to test activin A-targeted therapies.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...